Study Group: Medical Devices Financial Statement Analysts

Council Members in this Study Group: 23

This study group may include chief financial officers, chartered public accountants, controllers, and consultants knowledgeable on topics such as finance, taxation, auditing, forensic accounting and fraud, financial accounting and reporting, bankruptcy, pension benefits, cash flow, company valuation, working capital, hedge accounting, and mergers and acquisition, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Ronald Kiima

President
Kiima Incorporated

Ronald A. Kiima is a former SEC Assistant Chief Accountant. Mr. Kiima is currently the President of Kiima Incorporated, a private consulting firm specializing in SEC accounting and disclosure issues, SEC registration statements and periodic reports,...

Anthony Catanach

Director
DI2 Associates, LLC

Anthony H. Catanach Jr., PhD, is a Professor in the Strategic Initiatives Group of the Villanova University School of Business. He also is a Director at DI2 Associates, a Pennsylvania based accounting and reporting consulting firm. Dr. Catanach has expertise...

Alfred Blazek

Chief Financial Officer
Dunham's Sports

Alfred S. Blazek is the Chief Financial Officer of Dunham's Sports. He was until October 2008, Finance Director with Whirlpool. Mr. Blazek has served as the Chief Financial Officer for Circuit City's National Service group and a member of the corporate...

Eli Bartov

Professor
NEW YORK UNIVERSITY (INC)

Dr. Bartov, PhD, CPA, is a Research Professor of Accounting at the Stern School of Business, New York University. He has authored numerous scholarly articles on issues of accounting earnings manipulations, earnings quality, equity valuation, executive...

Paul Miller

Professor
REGENTS OF THE UNIVERSITY OF COLORADO

Paul Miller, PhD, is a Professor of Accounting at the University of Colorado at Colorado Springs. Dr. Miller has over 35 years of teaching, professional, and regulatory experience in financial reporting, GAAP, with service on the staffs of both FASB and...

View all Leading Experts in this Study Group

GLG News^SM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

More Under Armour Red Flags...

November 20, 2009

Analysis by:Anthony Catanach, Director,

Analysis of:Stock Jocks Punish Under Armour's Mathletes | www.cnbc.com

Under Armour's most recent 10K contains a number of financial reporting "red flags" that reflect a cavalier attitude toward financial reporting transparency.

What the Former SEC Chairmen Missed...

November 19, 2009

Analysis by:Anthony Catanach, Director,

Analysis of:Don't Let Banks Hide Bad Assets | online.wsj.com

Conceptually, the arguments favoring fair value accounting are sound and quite appealing. Unquestionably, financial statement users will benefit from data about how a company’s assets and liabilities change in value during a reporting period. However, there are two major issues associated with fair value reporting that accountants, investors, legislators, and regulators need to address in the wake of our most recent financial crisis.

What Have the Accountants Done For Us Lately?

November 19, 2009

Analysis by:Anthony Catanach, Director,

Analysis of:Systemic risk legislation threatens FASB’s independence | www.accountingweb.com

Debates about the causes of the recent financial crisis have yet to focus on the inability of financial institution independent auditors to provide adequate oversight over management’s valuations of financial instruments.

Truth is truth, whether it's welcome news or not

July 7, 2009

Analysis by:Paul Miller, Professor,

Analysis of:The Fair Value Deadbeat Debate Returns | www.cfo.com

Financial reporting works best, and maybe only, when it is complete and unbiased. If it is biased to manage the message, it becomes a method of distributing propaganda and all credibility is lost.The economics of gain occurrence is unarguable. If management can retire a debt for a smaller amount than the carrying value, then there are fewer liabilities and more equity. More equity means income has occurred. There is no rationality behind efforts to suppress truthful news just because you don't like it. Let's all hope the standard setters are not swayed by "visceral" impulses into the direction of keeping useful information out of financial statements. The inevitable consequence is greater risk and discounted share and bond prices, simply because users don't have access to the truth. That does no one any good.

Exacerbation or exposé?

October 13, 2008

Analysis by:Paul Miller, Professor,

Analysis of:Alls Fair: The Crisis and Fair-Value Accounting | www.cfo.com

undefined undefined Listen to the message and don’t shoot the messenger if you think it’s bad news. And don’t endorse public policies based on deceptive reporting. undefined undefined

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

Academic Institution*
Consulting Firm
Medical Device/Supplies Distributor
Independent Consulting Firm
Strategic Management
Biotechnology Manufacturer
Boutique Investment Bank
Sporting Goods Retailer
Medical Device Manufacturer
Staffing and Recruiting Services - Retained
Pharmaceuticals Manufacturer
Tax Firm
Medical Equipment & Supplies Manufacturer
Advocacy Group or Issue Focused

Members in this Study Group often have these job titles:

Professor
Chief Financial Officer
Principal
VP Finance
Owner
Consultant
Valuation / M&A Director
Director
Market Analyst
Chief Operating Officer
Managing Director
Controller
General Manager

Related Study Groups

Study Group Name	No. Members
Financial Statement Analysts - Leaders, Scholars, and Educators	353
US GAAP Healthcare Specialists	337
Software Financial Statement Analysts	36
Retail Industry Financial Statement Analysts	25
Current or Former Chief Financial Officers in the Medical Devices and Supplies Industry	78
Biopharmaceutical Financial Statement Analysts	30
US GAAP Academic Specialists	182
Stock Repurchase Accounting Academic Experts	14